All News

6 September 2007

Access and Somanta Announce New Data on Angiolix(R) Humanized Monoclonal AntibodyAntibodies

6 September 2007

Dyax Corp. and Bayer Schering Pharma AG Enter Into a Collaboration Agreement for Discovery of Therapeutic AntibodiesAntibodies

6 September 2007

Medarex Announces Extension of Broad Antibody Development Relationship with CentocorAntibodies

5 September 2007

Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization ProcessAntibodies

5 September 2007

YM BioSciences Announces positive preliminary results from Phase I/II lung cancer trial of nimotuzumab combined with radiationAntibodies

4 September 2007

Merck Applies to Extend Use of Erbitux(R) for 1st-Line Colorectal CancerAntibodies

31 August 2007

YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancerAntibodies

30 August 2007

Merck Serono to Reconsider Development of Matuzumab in Metastatic Colorectal Cancer PatientsAntibodies

30 August 2007

Phase II Study of IMC-A12 for Advanced Prostate Cancer Commences Patient EnrollmentAntibodies

29 August 2007

XOMA Licenses Antibody Technology to PfizerAntibodies

29 August 2007

Baxter and the Alzheimer’s Disease Cooperative Study Group to Pursue a Phase III Study of Gammagard Liquid in Patients with Alzheimer’s DiseaseAntibodies

25 August 2007

Genentech announces resubmission of supplemental Biologics License Application for Avastin in combination with Paclitaxel for first-line metastatic breast cancerAntibodies

25 August 2007

Avastin approved in Europe for first-line treatment of patients with advanced lung cancerAntibodies

25 August 2007

Phase II study of IMC-1121B for advanced renal cell cancer opens for patient enrollmentAntibodies

24 August 2007

Phase 3 Oncology Program for Aflibercept (VEGF Trap) InitiatedAntibodies

23 August 2007

MedImmune’s motavizumab reduced RSV hospitalizations by 83 percent among high-risk native American, full-term infants in placebo-controlled Phase 3 studyAntibodies

22 August 2007

Protox acquires research program from MedicennaAntibodies

22 August 2007

YM BioSciences’, European partner, Oncoscience AG, announces initiation of advanced nimotuzumab trials in adult glioma and pancreatic cancerAntibodies

22 August 2007

YM BioSciences’, European partner, Oncoscience AG, announces initiation of advanced nimotuzumab trials in adult glioma and pancreatic cancerAntibodies

21 August 2007

PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical TrialsAntibodies

21 August 2007

Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human PrimatesAntibodies

17 August 2007

Auxilium Pharmaceuticals, Inc. receives clearance to resume clinical trials for XIAFLEX(TM)Antibodies

17 August 2007

Anadis to use its polyclonal antibodies for treatmentAntibodies

16 August 2007

Cell Therapeutics, Inc. (CTI) enters agreement to acquire lymphoma drug Zevalin(R) from Biogen Idec for sales and marketing in the United StatesAntibodies

15 August 2007

Oncoscience AG, the european partner of YM BioSciences, announces completion of patient enrollment in phase III brain cancer trial of nimotuzabAntibodies

11 August 2007

Roche files IND for second Genmab antibodyAntibodies

10 August 2007

Rilonacept (IL-1 Trap) granted FDA priority review for the treatment of CAPSAntibodies

9 August 2007

InNexus Biotechnology unveils new platform for augmenting antibody therapeuticsAntibodies

9 August 2007

ORENCIA(R) (abatacept) supplemental biologics license application for juvenile idiopathic arthritis accepted by FDA for filing and reviewAntibodies

8 August 2007

Intellect Neurosciences, Inc. and Medical Research Council Technology (U.K.) Enter into Agreement to Humanize Two Monoclonal Antibodies for the Treatment of Alzheimer’s DiseaseAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

GPC3-Targeted Immunotherapy Pipeline Review

TSLP Pipeline Review

Bispecific Antibodies for Immuno-Oncology & Other Diseases

TL1A Inhibitor Pipeline Review

Blockbuster Biologics 2017: Sales of Recombinant Therapeutic Antibodies & Proteins

Report Package: TCR-Based Antibody and T-Cell Immunotherapy

CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing

Ranibizumab (Lucentis) Biosimilars Pipeline Review

Report Package: “Drug the Undruggable” Technologies

Eculizumab (Soliris) Biosimilars & Biosuperiors Pipeline Review